Leerink Partnrs Has Bearish Outlook for AVDL FY2025 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Investment analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $0.95 per share for the year, down from their prior forecast of $1.05. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.50) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2026 earnings at $2.00 EPS and FY2028 earnings at $3.15 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The firm had revenue of $50.00 million for the quarter, compared to analyst estimates of $48.43 million. Avadel Pharmaceuticals had a negative return on equity of 92.12% and a negative net margin of 52.53%. The company’s revenue was up 624.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.41) earnings per share.

AVDL has been the subject of several other reports. Oppenheimer lifted their price target on shares of Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. HC Wainwright dropped their price target on Avadel Pharmaceuticals from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Avadel Pharmaceuticals in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $24.43.

Avadel Pharmaceuticals Stock Down 3.6 %

Avadel Pharmaceuticals stock opened at $11.59 on Thursday. The company has a market capitalization of $1.12 billion, a PE ratio of -14.67 and a beta of 1.47. Avadel Pharmaceuticals has a 12-month low of $10.39 and a 12-month high of $19.09. The firm’s fifty day moving average is $13.62 and its 200 day moving average is $15.09.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Creative Planning raised its holdings in shares of Avadel Pharmaceuticals by 8.2% in the third quarter. Creative Planning now owns 12,381 shares of the company’s stock valued at $162,000 after purchasing an additional 938 shares during the last quarter. MAI Capital Management increased its stake in Avadel Pharmaceuticals by 1.0% in the 3rd quarter. MAI Capital Management now owns 107,533 shares of the company’s stock valued at $1,410,000 after buying an additional 1,031 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Avadel Pharmaceuticals by 60.5% during the 1st quarter. BNP Paribas Financial Markets now owns 4,469 shares of the company’s stock worth $75,000 after buying an additional 1,685 shares in the last quarter. Investors Asset Management of Georgia Inc. GA ADV boosted its stake in shares of Avadel Pharmaceuticals by 2.4% in the 2nd quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 89,475 shares of the company’s stock worth $1,258,000 after buying an additional 2,100 shares during the last quarter. Finally, Modera Wealth Management LLC grew its holdings in shares of Avadel Pharmaceuticals by 0.4% in the second quarter. Modera Wealth Management LLC now owns 602,608 shares of the company’s stock valued at $8,473,000 after acquiring an additional 2,159 shares in the last quarter. 69.19% of the stock is currently owned by institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.